The DOI matches its Crossref record.
Heparanase Gene Silencing, Tumor Invasiveness, Angiogenesis, and Metastasis
Open accessAbstract
BACKGROUND: Heparanase is an endoglycosidase that degrades heparan sulfate, the main polysaccharide constituent of the extracellular matrix and basement membrane. Expression of the heparanase gene is associated with the invasive, angiogenic, and metastatic potential of diverse malignant tumors and cell lines. We used gene-silencing strategies to evaluate the role of heparanase in malignancy and to explore the therapeutic potential of its specific targeting. METHODS: We designed plasmid vectors to express hammerhead ribozymes or small interfering RNAs (siRNAs) directed against the human or mouse heparanase mRNAs. Human breast carcinoma (MDA-MB-435) and mouse lymphoma (Eb) and melanoma (B16-BL6) tumor cell lines, which have naturally high levels of endogenous heparanase or have been genetically engineered to overexpress heparanase, were transfected with anti-heparanase ribozyme or siRNA. Semiquantitative reverse transcription-polymerase chain reaction (RT-PCR) and measurements of enzymatic activity were used to confirm the efficient silencing of heparanase gene expression. Cells transfected with the anti-heparanase ribozyme and siRNA vectors were tested for invasiveness in vitro and metastatic dissemination in animal models of experimental and spontaneous metastasis. RESULTS: Compared with cells transfected with control constructs, cells transfected with the anti-heparanase ribozyme or siRNA vectors had profoundly reduced invasion and adhesion in vitro, regardless of cell type, and expressed less heparanase. In vivo, tumors produced by cells transfected with the anti-heparanase ribozyme and siRNA vectors were less vascularized and less metastatic than tumors produced by cells transfected with the control vectors. Mice injected with cells transfected with the anti-heparanase ribozyme and siRNA vectors lived longer than mice injected with control cells. CONCLUSIONS: The association of reduced levels of heparanase and altered tumorigenic properties in cells with anti-heparanase ribozyme- or siRNA-mediated gene-silencing vectors suggests that heparanase is important in cancer progression. Heparanase gene silencing has potential use as a target for anticancer drug development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The tumor microenvironment at a glance
Balkwill, F. R., Capasso, M., & Hagemann, T. (2012) · Journal of Cell Science · doi:10.1242/jcs.116392 · Cited by 1,857
Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis
Ilan, N., Elkin, M., & Vlodavsky, I. (2006) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2006.06.004 · Cited by 524
Self-citationProspects of RNA interference therapy for cancer
Pai, S. I., Lin, Y.-Y., Macaes, B., Meneshian, A., Hung, C.-F., & Wu, T.-C. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302694 · Cited by 352
Heparanase, Hyaluronan, and CD44 in Cancers: A Breast Carcinoma Perspective
Götte, M., & Yip, G. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1464 · Cited by 340
Heparanase activates the syndecan-syntenin-ALIX exosome pathway
Roucourt, B., Meeussen, S., Bao, J., Zimmermann, P., & David, G. (2015) · Cell Research · doi:10.1038/cr.2015.29 · Cited by 330
Metadata
- Authors
- Edovitsky, E., Elkin, M., Zcharia, E., Peretz, T., & Vlodavsky, I.
- Venue
- JNCI Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-08-17
- Volume
- 96
- Issue
- 16
- Pages
- 1219-1230
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2150802762
- Cited by
- 242
- References
- 0
- FWCI
- 7.60
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Heparanase Gene Silencing, Tumor Invasiveness, Angiogenesis, and Metastasis. https://app.cochat.ai/papers/10.1093/jnci/djh230
- The paper
- Edovitsky, E., Elkin, M., Zcharia, E., Peretz, T., & Vlodavsky, I. (2004). Heparanase Gene Silencing, Tumor Invasiveness, Angiogenesis, and Metastasis. JNCI Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djh230
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.